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Summary Peripheral blood from 67 patients with non-Hodgkin's lymphoma was examined at initial
diagnosis for the presence of circulating lymphoma cells by DNA hybridisation using immunoglobulin and
T-cell receptor gene probes. Clonal gene rearrangement was found in 31% (21/67) of patients and correlated
with clinical stage, histological grade and bone marrow involvement. Clinical stage and the presence of
lymphoma cells in peripheral blood were prognostic factors for progression-free survival in all patients on
univariate analysis, but the detection of lymphoma cells was not independent of stage. It was also not a
significant predictor for survival. In patients with intermediate- and high-grade lymphoma, the detection of
lymphoma cells in peripheral blood was a significant prognostic factor for progression-free survival (PFS) and
survival only on univariate analysis. The 3-year PFS was 17% in patients with circulating lymphoma cells
compared with 75% if these were absent (P<0.05). The presence of lymphoma cells in peripheral blood is
associated with extensive disease and may be a biological marker of poor disease control. Sensitive techniques
of detection should form part of large prospective studies in non-Hodgkin's lymphoma.
Lymphoma cells can be identified in peripheral blood of
patients with non-Hodgkin's lymphoma (NHL) by a number
of techniques. They can be seen by simple morphological
examination of peripheral blood smear in 8-20% of patients
(Come et al., 1980; Dick et al., 1974; Foucar et al., 1982;
McKenna et al., 1975; Morra et al., 1985). The clonal nature
of lymphoma allows for the detection of lymphoma cells by
techniques relying on clonality. With the immunocytological
technique of 'clonal excess' using ic/A staining combined with
flow cytometry it is possible to identify a clonal lymphoid
population in peripheral blood with 1-10% sensitivity (Ber-
liner et al., 1986). However, techniques relying on surface
immunoglobulin are limited to B-cell lymphomas and the
sensitivity depends on the degree of immunoglobulin expres-
sion.
Clonal immunoglobulin and T-cell receptor gene rear-
rangement can be detected by DNA hybridisation techniques
with immunoglobulin and T-cell receptor gene probes as
faint bands of rearrangement assumed to represent lym-
phoma cells (Brada, 1990). Circulating lymphoma cells can
be detected with 1-5% sensitivity (Brada et al., 1987;
Knowles et al., 1987; Wright et al., 1987), and this is more
sensitive than the technique of clonal excess (Berliner et al.,
1986). The sensitivity can be markedly increased by the use
of polymerase chain reaction (PCR). However, this requires
either the presence of a specific translocation such as the
t(14;18) or the knowledge of specific sequence around the
gene rearrangement site. The sensitivity reaches 1:105 and has
been applied particularly to the study of low-grade lym-
phoma (Cotter et al., 1990).
Despite extensive literature on the frequency and the tech-
niques of detection of circulating lymphoma cells, there is
little information on the clinical significance of these findings.
The presence ofclonal excess in remission seems to bear little
relationship to the disease outcome, both in intermediate-
and high-grade lymphoma (Horning et al., 1990; Johnson et
al., 1991) and in low-grade lymphoma when cells are detected
with high sensitivity by PCR (Cotter et al., 1990; Price et al.,
1991). We have embarked on a prospective study to detect
lymphoma cells in the peripheral blood at presentation using
immunoglobulin and T-cell receptor gene rearrangement.
Patients received treatment independently of the peripheral
blood findings according to The Royal Marsden Hospital
protocols. This study attempts to correlate initial peripheral
blood findings and the clinical course of the disease and to
assess the prognostic significance of the presence of lym-
phoma cells in peripheral blood.
Patients and methods
Between 1986 and 1990, 90 patients with previously un-
treated non-Hodgkin's lymphoma (NHL) had a peripheral
blood sample taken for analysis. The NHL was confirmed on
histological review of initial biopsy specimen in all patients.
Lymphoma was classified according to the International
Working Formulation (The Non-Hodgkin's Lymphoma
Pathologic Classification Project, 1982). One patient with
primary cerebral lymphoma was not included in further
analysis. There was insufficient DNA available for analysis in
22 samples. The peripheral blood samples from the remaining
67 patients had full DNA analysis and the results were
correlated with clinical details.
Patients were aged 20-87 years (median 57); 36 were male
and 31 female. Twenty-six patients had low-grade and 41
intermediate- and high-grade disease. Clinical staging
included routine haematological and biochemical tests as well
as CT scan of chest and abdomen and bone marrow
examination. Thirty-one patients had clinical stage (CS) I
and II disease and 36 CSIII and IV disease. Twenty-five
patients had disease confined to nodal sites alone and 42
patients had extranodal involvement; 15 patients had bone
marrow involvement.
Treatment
Patients were treated according to the protocols at the time
of presentation. The overall treatment approach is listed in
Table I. Of 13 patients with low-grade disease on initial
surveillance, ten had stage III and IV disease and three
extensive stage II disease. Of nine patients with stage I and II
low-grade NHL, four received radiotherapy and two with
more extensive disease had chlorambucil-based
chemotherapy. Of 22 patients with stage I and II
intermediate- and high-grade disease, five received
radiotherapy alone, six chemotherapy alone and 11 combined
chemotherapy and radiotherapy. All patients with advanced
aggressive disease received initial chemotherapy and three
had additional radiotherapy. The specific chemotherapy in
patients with intermediate- and high-grade lymphoma con-
sisted of CHOP and variants in 11 patients, a mitozantrone-
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Table I Initial treatment and the detection ofclonality in peripheral
blood in 67 patients with NHL
Histological grade
Treatment Low Intermediate and high
approaches ClonaP Non-clonalP Clonal Non-clonal
Surveillance 7 6 - -
Chemotherapy alone 3 6 7 13
Chemotherapy and - - 2 14
radiotherapy
Radiotherapy alone 2 2 - 5
Total 12 14 9 32
aClonal, clonal rearrangement detected in peripheral blood. bNon
clonal, rearrangement not detected in peripheral blood.
based regimen in 10, MACOP-B in 13 and a chlorambucil-
based regimen in two patients with follicular intermediate-
grade disease.
Patients were followed by clinical examination, routine
chest radiograph, and blood count. The median follow-up
was 31 years (range 11 months to 7 years). Disease recur-
rence or progression was determined by clinical examination
and imaging. Progression-free survival (PFS) and survival
were measured from the date of diagnosis and were cal-
culated by the actuarial method (Peto et al., 1977). Patients
on initial surveillance had PFS measured from the date of
starting therapy. Comparison between subgroups was made
by log-rank analysis (Peto et al., 1977) and the independent
prognostic significance was tested using the Cox regression
model (Cox et al., 1972).
Methods ofdetection oflymphoma cells
A 20 ml sample of peripheral blood was seperated on Lym-
phoprep (Nycomed) density gradient and the mononuclear
cell fraction isolated. DNA was extracted by conventional
techniques and digested with appropriate restriction enzymes
(EcoRI, HindIII, BamHI, BglII, PstI, XbaI) under the condi-
tions recommended by the suppliers (Boehringer Mannheim).
At least two different digests were performed for hybridisa-
tion with each of the probes. The DNA was fractionated on
0.7% agarose gels (BRL) together with positive and negative
controls and appropriate size markers (lHindlII digest; Boeh-
ringer Mannheim), photographed, and transferred to nylon
membrane (Hybond-N; Amersham International) by conven-
tional Southern blotting. The DNA was fixed to the mem-
branes using mid-range UV transillumination. The memb-
ranes were hybridised at 65°C for 16 h with the appropriate
probes, previously labelled with 32P by the random primer
extension method (Feinberg & Vogelstein et al., 1983) in a
solution of 6 x SSPE (20 x SSPE: 0.17 M sodium phosphate,
2.98 M sodium chloride, 0.02 M EDTA), 5 x Denhardt's (1%
bovine serum albumin, 1% Ficoll, 1% polyvinyl pyr-
rolidone), 5% dextran sulphate and 0.5% sodium dodecyl
sulphate (SDS). Filters were washed to a stringency of
0.1 x SSPE at 650C. A circulating clone of cells was con-
sidered to be present if one or two rearranged bands in
addition to germline bands were present on two separate
enzyme digests. Where sufficient DNA was obtained tests
were done for both immunoglobulin and T-cell receptor gene
rearrangement, regardless of immunophenotype. In eight
cases with insufficient DNA material the immunophenotype
of the diagnostic lymph node was indicative of a B-cell
malignancy, and the peripheral blood was examined only for
rearrangements of the immunoglobulin genes.
Lymph node tissue for DNA analysis was snap frozen at
biopsy and disaggregated by homogenisation. DNA was ex-
tracted and treated as for peripheral blood.
DNA probes
To establish clonality of B cells JH probe, homologous to the
joining region of the immunoglobulin heavy-chain gene (a
gift from P. Leder), was used, which is present in both
rearranged and unrearranged alleles (Ravetch et al., 1981).
The T-cell receptor probe used was Cp1 (Furley et al., 1986)
(a gift from T. Mak), homologous to the Cp1 region of the
P-chain of the T-cell receptor gene, which is expressed as an
o4p dimer in 90% of T cells (Elliot et- al., 1988).
Results
Frequency ofperipheral blood involvement
Clonal rearrangement was found in the peripheral blood of
21 of 67 patients (31%) at the time of presentation of NHL.
The frequency of detection of lymphoma cells by stage and
histology is shown in Table II. Clonal rearrangement was
more frequently found in patients with advanced disease
(stages III and IV, 42%) compared with local disease (stages
I and II, 19%) (P<0.05) and in patients with low-grade
compared with intermediate- and high-grade disease (46% vs
22%) (P= 0.05). Bone marrow involvement was also
associated with a higher prevalence of circulating lymphoma
cells. Of 15 patients with bone marrow disease, ten had
clonal rearrangement in peripheral blood (67%), while only
11 of 52 patients with negative bone marrow (21%) had
peripheral blood involvement (P<0.001). The prevalence of
gene rearrangement in peripheral blood did not correlate
with the presence of extranodal disease and age.
Outcome andprognosticfactors
The details of specific treatment and the frequency of detec-
tion of clonal rearrangement are shown in Table I. The
overall 3-year PFS of 67 patients was 48% and survival 71%.
Twenty-two of 41 patients with intermediate- and high-grade
NHL achieved complete response and 13 partial response.
A number of factors were analysed for their prognostic
significance for survival (Table III) and PFS (Table IV).
Clinical stage and age were significant prognostic factors for
survival on univariate analysis and multivariate analysis.
Stage, histological grade and the presence of clonal rear-
rangement in peripheral blood were significant prognostic
factors for PFS on univariate analysis. The 3-year PFS of 21
patients with circulating lymphoma cells was 16% (median
PFS 14 months) and the 3-year PFS of 43 patients without
clonal rearrangement in peripheral blood 69% (P<0.005).
On multivariate analysis stage remained a significant prog-
nostic factor for PFS, while peripheral blood involvement
only reached marginal significance (Table IV).
The results were stratified by histological grade and the
analysis by prognostic factors for intermediate- and high-
grade lymphoma is shown in Table V. Stage and the presence
of circulating lymphoma cells were significant prognostic fac-
tors for survival and PFS. The 3-year PFS of nine patients
with clonal rearrangement was 17% compared with 75% of
32 patients without rearrangement (P<0.005). Only clinical
stage remained an independent prognostic factor for survival
and PFS on multivariate analysis (Table IV). In patients with
low-grade lymphoma the 3-year progression-free survival was
8% in 12 patients with clonal rearrangement and 38% in 14
patients without (P<0.01).
Table II Comparison of the incidence of clonal rearrangement in
peripheral blood at presentation with histological grade and clinical
stage of disease
Number ofpatients with clonal gene rearrangement
in peripheral blood/number tested (%)
Intermediate and
Clinical stage Low grade high grade Total
I and II 3/9 (33%) 3/22 (14%) 6/31 (19%)
III and IV 9/17 (53%) 6/19 (32%) 15/36 (42%)
Total 12/26 (46%) 9/41 (22%) 21/67 (31%)PERIPHERAL BLOOD INVOLVEMENT IN NON-HODGKIN'S LYMPHOMA 349
Table HI Survival of 67 patients with NHL. Prognostic factors on univariate
and multivariate analysis
Three-year Signif.
No. of survival Signif. multi.
Characteristic patients (%) uni. (RR)
All 67 71 - -
Sex
Male 36 69 NS NS
Female 31 73
Age P = 0.03
<40 15 93 P<0.05 (1.0)
>40 52 65 (3.3)
Stage P = 0.05
I and II 31 82 P<0025 (1.0)
III and IV 36 62 (2.4)
Site
Nodal 25 68 NS NS
Extranodal 42 73
Bone marrow
Involved 15 87 NS NS
Not involved 52 67NS N
Grade
Low 26 76NSS Intermediate and high 41 70 NS NS
Peripheral blood gene
rearrangement
Clonal 21 61 NS NS
Non-clonal 46 77
Signif. uni., statistical significance on univariate analysis; signif. multi.,
statistical significance on multivariate analysis; NS, not statistically significant;
RR, relative risk.
Table IV Progression-free survival (PFS) of 64a patients with NHL.
Prognostic factors on univariate and multivariate analysis
Three-year Signif
No. of PFS Signif. multi.
Characteristic patients (%) uni. (RR)
All 64 55 -
Sex
Male 35 58NSS Female 29 50 NS NS
Age
< 40 14 51 NS NS
Stage
I and II 31 73 P <0 5 P=0.005
III and IV 33 35 (2.8)
Bone marrow
Involved 14 35 NS NS
Not involved 50 61
Grade
Low 23 28 < 0 N
Intermediate and high 41 66 P<0.05 NS
Peripheral blood gene
rearrangement
Clonal 21 16 P =0.08
Non-clonal 43 69 P<0.01 (2.1)
aThree patients with low-grade NHL remaining on surveillance were
excluded.
Discussion
DNA hybridisation studies of the mononuclear cell fraction
from peripheral blood of patients with non-Hodgkin's lym-
phoma detect clonal rearrangement of immunoglobulin and
T-cell receptor genes. In ten patients in this study lymphoma
tissue was available for analysis, and in four cases in which
rearrangement was found in peripheral blood this was iden-
tical to that in the lymphoma tissue. This is similar to
previous findings and indicates that such gene rearrangement
represents lymphoma cells (Brada et al., 1987; Hu et al.,
1985).
As shown previously, the sensitivity of detection of lym-
phoma cells was 1-5% (Berliner et al., 1986; Brada et al.,
1987; Horning et al., 1990). The overall frequency of detec-
tion of lymphoma cells (31%) compares with other studies350 L.R. HIORNS et al.
Table V Prognostic factors for survival and progression-free survival (PFS) in 41 patients with intermediate- and
high-grade lymphoma
Three-year Signif. Three-year
No. of survival Signif multi. PFS Signif. Signif.
Characteristic patients (%) uni. (RR) (%) uni. multi.
All 41 70 - - 65 -
Sex
Male 22 64 NS NS 74 NS NS
Female 19 78 56
Age
< 40 13 63 NS NS 96 NS NS
Stage P= 0.02 P<0.005
I and II 22 86 P<0.025 (1.0) 90 P<o.005 (1.0)
III and IV 19 53 (4.2) 35 (9.6)
Site
Nodal 13 67 NS NS 72 NS NS Extranodal 28 71 63
Bone marrow
Involved 7 86 NS NS 5 S N Not involved 34 67 NS NS 68
Peripheral blood gene
rearrangement
Non-clonal 32 78 P<0.05 NS 75 P<0.05 NS
Signif. uni., statistical significance on univariate analysis; signif. multi., statistical significance on multivariate
analysis; NS, not statistically significant; RR, relative risk.
(Brada et al., 1987; Horning et al., 1990; Johnson et al.,
1991), which suggest that similar sensitivity was retained. The
rate of detection correlated with stage, histological grade and
the presence of bone marrow involvement as reported
previously (Brada et al., 1987; Homing et al., 1990).
Although the presence of circulating cells was related to the
stage of disease and bone marrow involvement, a number of
patients with early stage disease and without bone marrow
involvement had clonal rearrangement in peripheral blood.
The distribution of patients by stage, histological grade
and age broadly reflects the spectrum of the lymphoma
patient population (DeVita et al., 1985). Although the treat-
ment in terms of individual regimens was not uniform, most
patients with intermediate- and high-grade lymphoma were
treated with anthracycline-containing chemotherapy and
patients with localised disease were treated with combined
chemotherapy and radiotherapy. Only five patients with local
disease were treated with radiotherapy alone. Treatment of
low-grade NHL also followed established practice. Half of
the patients with advanced low-grade lymphoma were sub-
jected to a policy of initial observation, while a third received
initial chemotherapy. Patients with localised low-grade NHL
were treated with radiotherapy alone. The prognostic
influence of stage and histology reflects the prognostic factors
found in other studies, although the limited number of
patients precludes a more exhaustive analysis.
The detection of lymphoma cells in peripheral blood cor-
related with poor disease control in the whole group and in
those with intermediate- and high-grade lymphoma. Mul-
tivariate analysis suggested that the presence of lymphoma
cells is only a marginal independent prognostic factor for
PFS in the combined group as it did not fully reach statis-
tical significance. These findings are similar to those of
Lindemalm et al. (1987), who found that the detection of
circulating lymphoma cells by clonal B-cell excess correlated
with poor disease-free survival in patients with high-grade
lymphoma. However, it is difficult to reconcile these data
with the finding that the presence of lymphoma cells in
patients in remission does not predict subsequent relapse
(Homing et al., 1990).
Clones of lymphoma cells are found frequently in patients
with low-grade NHL (Cotter et al., 1990). With highly
sensitive techniques such as PCR their detection does not
correlate with prognosis. The presence of cells in patients in
long-term remission also does not predict early relapse (Price
et al., 1991).
Although the presence of lymphoma cells may correlate
with worse disease control, the results have to be interpreted
with caution. The group of patients studied is small and
heterogeneous and the treatment approach was also not
uniform. Nevertheless the patients studied broadly reflect an
unselected population of patients with lymphoma presenting
at an oncology centre. If these results are confirmed the
presence of lymphoma cells would provide a biological
marker of poor disease control.
Lymphoma cells in peripheral blood reflect not only the
extent of disease and tumour burden as defined by clinical
stage and extranodal (particularly bone marrow) involve-
ment, but also a biological property of entry of solid tumour
cells into the circulation. Disease recurrence is due either to
incomplete remission in patients with extensive tumour
burden or to chemoresistance. Relapse from apparently com-
plete remission is due to survival of chemoresistant cells or
cells not reached by chemotherapy. It is difficult to present a
rationale for the link between chemoresistance and recircula-
tion of lymphoma cells, although both may represent the
same extreme of biological behaviour. It is also possible that
circulating cells in intermediate- and high-grade lymphoma
may temporarily reside at sites poorly accessible to
chemotherapy.
In conclusion, the detection of circulating lymphoma cells
by the sensitive technology of DNA hybridisation with
immunoglobulin and T-cell receptor probes may be associ-
ated with worse disease control but so far does not appear to
be independent of stage. The presence of lymphoma cells in
peripheral blood represents a biological phenomenon, the
determinants of which are currently not defined. More sen-
sitive techniques of detection using PCR have been tested in
low-grade lymphoma. Although suitable for individual cases
of intermediate- and high-grade lymphoma, PCR is not cur-
rently applicable for large studies. In addition, the
significance of detection of very small numbers of lymphoma
cells by PCR is not clear, except in patients undergoing
high-dose chemotherapy and bone marrow transplantationPERIPHERAL BLOOD INVOLVEMENT IN NON-HODGKIN'S LYMPHOMA 351
with marrow purging (Gribben et al., 1991). The study of
peripheral blood involvement in patients presenting with lym-
phoma using DNA technology should be included in large
multicentre trials with uniform treatment to define the precise
prognostic significance of these findings.
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